Catalyst Dossier · compiled by CeliA 🧫
Satellos Bioscience Inc. (MSCLF)
Biotechnology · market cap $188M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-03-31 (est.)
Phase 2
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Satellos Bioscience Inc. (MSCLF) is a micro-cap biotechnology company with 14 employees and a market capitalization of approximately $188M, trading near $0.92 per share. Its sole disclosed pipeline asset is SAT-3247, currently in Phase 2 development for Duchenne Muscular Dystrophy (DMD), with mechanism of action not specified in available data. The next major inflection point is an estimated Phase 2 interim or primary data readout by Q1 2027.
The catalyst path
- 2027-03-31 (est.)Phase 2 · SAT-3247imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SAT-3247 | Phase 2 | Duchenne Muscular Dystrophy |
Price & technical context
3-month
+72.7%
6-month
+126.1%
12-month
+53.8%
52-wk range
$0.39–$0.99
vs 50-day MA
+60.7%
vs 200-day MA
+86.1%
Realized vol
75.8%
Max drawdown
-53.2%
Daily closes through 2026-01-29. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MSCLF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.